Mirum (NASDAQ: MIRM) insider files Form 144 stock sale plan

Rhea-AI Filing Summary

Mirum Pharmaceuticals insider Peter Radovich has filed a Form 144 to sell 3,143 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 304,619.56, out of 51,393,574 shares outstanding.

The shares were acquired on 01/23/2026 as restricted stock units vesting under a registered plan, as compensation for services to the issuer. The filing also notes that during the past three months Radovich sold 2,382 shares of common stock on 01/22/2026 for gross proceeds of 222,300.69.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 8th Floor New York NY 10004	3143	304619.56	51393574	01/26/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/23/2026	Restricted Stock Units vesting under registered plan	Issuer			3143	01/23/2026	Compensation for services rendered to Issuer

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Peter Radovich c/o Mirum Pharmaceuticals, Inc. 989 E Hillsdale Blvd., Suite 300 Foster City CA 94404	Common Stock	01/22/2026	2382	222300.69

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Mirum Pharmaceuticals (MIRM) Form 144 filing disclose?

The Form 144 discloses that insider Peter Radovich plans to sell 3,143 shares of Mirum Pharmaceuticals common stock. The planned sale has an aggregate market value of 304,619.56 and will be executed on the NASDAQ through Morgan Stanley Smith Barney LLC.

How many Mirum Pharmaceuticals (MIRM) shares is the insider planning to sell?

The filing shows a planned sale of 3,143 shares of Mirum Pharmaceuticals common stock. These shares have an aggregate market value of 304,619.56 and are part of a broader base of 51,393,574 shares of common stock outstanding at the time referenced.

How did the Mirum Pharmaceuticals insider acquire the shares being sold?

The shares being sold were acquired on 01/23/2026 as restricted stock units vesting under a registered plan. They were received from the issuer as compensation for services rendered, rather than purchased for cash in the open market or via another cash transaction.

Which broker and exchange are involved in the Mirum (MIRM) Form 144 sale?

The planned sale will be executed through Morgan Stanley Smith Barney LLC, located at 1 New York Plaza in New York. The shares are expected to be sold on the NASDAQ stock market, as specified in the Form 144 securities information table.

What prior Mirum Pharmaceuticals share sales are disclosed in this Form 144?

The filing reports that Peter Radovich previously sold 2,382 shares of Mirum Pharmaceuticals common stock on 01/22/2026. Those earlier sales generated gross proceeds of 222,300.69, and are listed in the section covering securities sold during the past three months.

What does the Form 144 say about the insider’s knowledge of Mirum (MIRM)?

By signing the notice, the person for whose account the securities are to be sold represents that they do not know any material adverse information about Mirum Pharmaceuticals’ current or prospective operations that has not been publicly disclosed, consistent with Rule 144 requirements.